Overview

* Ekso Bionics ( EKSO ) Q2 revenue of $2.1 mln missed analyst expectations

* Company reported net loss of $2.7 mln for Q2 2025

* Personal Health product sales grew over 50% yr/yr in H1 2025

Outlook

* Ekso anticipates recovery in H2 driven by Personal Health demand

* Ekso sees over 50% growth in Personal Health products Y-o-Y

* Company aims to meet anticipated Enterprise Health customer demand

Result Drivers

* ENTERPRISE HEALTH SALES - Revenue decline attributed to short-term delays in completing multi-device Enterprise Health sales, per CEO Scott Davis

* PERSONAL HEALTH GROWTH - Personal Health product sales grew over 50% year-over-year in H1 2025

* GROSS MARGIN PRESSURE - Gross margin decreased due to fixed costs and increased shipping costs, partially offset by improved service margins

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $2.06 $4.31

Revenue mln mln (2

Analysts

)

Q2 EPS -$1.24

Q2 Net $2.71

Ioss mln

Q2 $4.79

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Ekso Bionics Holdings Inc ( EKSO ) is $37.50, about 87.1% above its July 25 closing price of $4.82

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)